Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Oste...(s been demonstrated to promote repair of...),Health

Date:12/7/2007

s been demonstrated to promote repair of other hard tissues including bone and dentin," said Dr. David M. Rosen, Ph.D., Senior Vice President of Research and Development. Additional studies are in progress to more fully characterize the response and the optimal way to deliver AC-100 for cartilage repair.

Acologix, Inc.

Acologix, Inc. a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnered with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (TRK-820) for the treatment of uremic pruritus in dialysis patients. Acologix is preparing for a Phase III study with this compound for uremic pruritus in the United States for 2008. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, has been studied in two Phase II clinical studies; one in dental restoration procedures and another for the repair of periodontal defects. Further studies to support development in orthopedic indications are ongoing. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease. For more information, go to http://www.acologix.com.

Poster #416: "AC-100 Promotes Articular Surface Restoration and Subchondral Bone Healing in Osteochondral Defect Study in Goats." by Catherine Middleton-Hardie, Ph.D., David Rosen, Ph.D., Birthe Schnegelsberg, Ph.D., Mirella Lazarov, D.D.S, Ph.D., Robert Spiro, Ph.D. of Acologix, Harold Aberman, D.V.M., Tim Simon, Ph.D. of Applied Biological Concepts. Presented by Dr. Middleton-Hardie on Friday, December 7 and Saturday, December 8, 2007, at the Osteoarthritis Research Society International 2007
'/>"/>

SOURCE Acologix, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens